2018
Immunologic profile and prognostic significance of tumor-infiltrating lymphocytes in renal cell carcinoma.
Khan A, Jansen C, Wilkinson Carlisle J, Melnick K, Kim K, Hosseinzadeh F, Prokhnevska N, Bilen M, Master V, Kissick H. Immunologic profile and prognostic significance of tumor-infiltrating lymphocytes in renal cell carcinoma. Journal Of Clinical Oncology 2018, 36: 673-673. DOI: 10.1200/jco.2018.36.6_suppl.673.Peer-Reviewed Original ResearchUCLA Integrated Staging SystemTumor-infiltrating lymphocytesVenous tumor thrombusRenal cell carcinomaPrimary tumorCD8+Cell carcinomaPhenotype of tumor-infiltrating lymphocytesSignificance of tumor-infiltrating lymphocytesCo-inhibitory receptor expressionNon-metastatic primary tumorsHigher treatment failureCD8+ cellsIntegrated Staging SystemAssociated with recurrencePhenotype of primary tumorsMayo stageTIL levelsCD28+Tumor thrombusCo-stimulatoryEvaluate recurrencePrognostic factorsPrognostic scorePrognostic significance
2014
TIM-3, a Possible Target for Immunotherapy in Cancer and Chronic Viral Infections.
Tieu R, Amancha P, Villinger F, Byrareddy S. TIM-3, a Possible Target for Immunotherapy in Cancer and Chronic Viral Infections. 2014, 1 PMID: 26539564, PMCID: PMC4629856.Peer-Reviewed Original ResearchChronic viral infectionsTim-3Inhibitory receptorsChronic viral infection modelsEffector T cell responsesExpression of Tim-3Viral infectionCo-inhibitory moleculesT cell responsesCTLA-4PD-1Immune checkpointsCo-stimulatorySoluble factorsInfection modelTherapeutic targetImmunotherapyTumorReceptorsInfectionViral infection modelCancerChronicallyComplex mechanismsImmunotherapy in the treatment of non-small cell lung cancer
Sundar R, Soong R, Cho B, Brahmer J, Soo R. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85: 101-109. PMID: 24880938, PMCID: PMC4332778, DOI: 10.1016/j.lungcan.2014.05.005.Peer-Reviewed Educational MaterialsConceptsImmune response to tumorsTreatment of non-small cell lung cancerNon-small cell lung cancerProlonged clinical responsesImmune checkpoint modulatorsImmune checkpoint pathwaysPD-L1 inhibitorsResponse to tumorsCell lung cancerCTLA-4PD-1PD-L1Tolerable toxicityTumor immunosurveillanceCheckpoint modulatorsCo-stimulatoryCo-inhibitoryClinical responseImmunotherapeutic agentsPredictive biomarkersImmune destructionLung cancerTreatment selectionImmune systemInhibitory molecules
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply